AU2001275798A1 - 3,4-dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient - Google Patents
3,4-dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredientInfo
- Publication number
- AU2001275798A1 AU2001275798A1 AU2001275798A AU7579801A AU2001275798A1 AU 2001275798 A1 AU2001275798 A1 AU 2001275798A1 AU 2001275798 A AU2001275798 A AU 2001275798A AU 7579801 A AU7579801 A AU 7579801A AU 2001275798 A1 AU2001275798 A1 AU 2001275798A1
- Authority
- AU
- Australia
- Prior art keywords
- compounds
- active ingredient
- dihydroisoquinoline derivative
- drugs containing
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- -1 3,4-dihydroisoquinoline derivative compounds Chemical class 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000004550 Postoperative Pain Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000232911 | 2000-08-01 | ||
JP2000-232911 | 2000-08-01 | ||
PCT/JP2001/006541 WO2002010135A1 (fr) | 2000-08-01 | 2001-07-30 | Composes derives de 3,4-dihydroisoquinoline et medicaments contenant ces composes comme principe actif |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001275798A1 true AU2001275798A1 (en) | 2002-02-13 |
Family
ID=18725515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001275798A Abandoned AU2001275798A1 (en) | 2000-08-01 | 2001-07-30 | 3,4-dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient |
Country Status (20)
Country | Link |
---|---|
US (1) | US6956033B2 (fr) |
EP (1) | EP1306373B1 (fr) |
JP (1) | JP4982937B2 (fr) |
KR (1) | KR20030017660A (fr) |
CN (1) | CN1466577A (fr) |
AT (1) | ATE362470T1 (fr) |
AU (1) | AU2001275798A1 (fr) |
BR (1) | BR0112883A (fr) |
CA (1) | CA2417156A1 (fr) |
CZ (1) | CZ2003284A3 (fr) |
DE (1) | DE60128476D1 (fr) |
HU (1) | HUP0303070A2 (fr) |
IL (1) | IL154082A0 (fr) |
MX (1) | MXPA03000952A (fr) |
NO (1) | NO20030490L (fr) |
NZ (1) | NZ523839A (fr) |
PL (1) | PL362916A1 (fr) |
RU (1) | RU2272030C2 (fr) |
WO (1) | WO2002010135A1 (fr) |
ZA (1) | ZA200300619B (fr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003061699A1 (fr) * | 2001-12-27 | 2003-07-31 | Japan Tobacco, Inc. | Remedes pour affections allergiques |
US7378428B2 (en) * | 2002-01-31 | 2008-05-27 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient |
US20070027144A1 (en) * | 2003-08-18 | 2007-02-01 | Shionogi & Co., Ltd. | Novel use of cannabinoid receptor agonist |
TW200533657A (en) * | 2004-02-17 | 2005-10-16 | Esteve Labor Dr | Substituted pyrazoline compounds, their preparation and use as medicaments |
AR051596A1 (es) * | 2004-10-26 | 2007-01-24 | Irm Llc | Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios |
TWI360539B (en) * | 2004-10-28 | 2012-03-21 | Shionogi & Co | 3-carbamoyl-2-pyridone derivatives |
WO2006065686A2 (fr) * | 2004-12-13 | 2006-06-22 | Galileo Pharmaceuticals, Inc. | Derives spiro utilises en tant qu'inhibiteurs de lipoxygenase |
US20060160850A1 (en) | 2005-01-18 | 2006-07-20 | Chongqing Sun | Bicyclic heterocycles as cannabinoid receptor modulators |
EP1743890A1 (fr) * | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | Dérivés 4,5-dihydro-1H-pyrazole, leur, préparation et utilisation comme médicaments. |
US7897589B2 (en) * | 2005-07-15 | 2011-03-01 | Laboratorios Del Dr. Esteve, S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
EP1743892A1 (fr) * | 2005-07-15 | 2007-01-17 | Laboratorios del Dr. Esteve S.A. | Composés pyrazoline substitués, leur préparation et utilisation comme médicaments |
EP1757587A1 (fr) * | 2005-07-15 | 2007-02-28 | Laboratorios Del Dr. Esteve, S.A. | Composés de pyrazoline substituée, leur préparation et leur usage comme médicaments |
CN101394847B (zh) * | 2006-01-06 | 2017-05-24 | 塞普拉柯公司 | 作为单胺重摄取抑制剂的环烷基胺类 |
KR101373087B1 (ko) * | 2006-10-30 | 2014-03-11 | 산메디카루 가부시키가이샤 | 치과용 셀프 에칭 프라이머 조성물 |
US20100099673A1 (en) * | 2007-01-17 | 2010-04-22 | Bilodeau Mark T | Decahydroquinoline analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases |
JPWO2008111296A1 (ja) | 2007-03-09 | 2010-06-24 | 国立大学法人京都大学 | 角化の亢進に起因する皮膚疾患の予防及び治療のための医薬 |
EP2151234A1 (fr) * | 2008-07-28 | 2010-02-10 | Laboratorios Del. Dr. Esteve, S.A. | Formulation pharmaceutique comprenant un composé récepteur CB1 dans une solution solide et/ou une dispersion solide |
JP5770102B2 (ja) * | 2008-12-19 | 2015-08-26 | ジェネンテック, インコーポレイテッド | 複素環化合物と使用方法 |
US8569504B2 (en) | 2009-06-17 | 2013-10-29 | Ono Pharmaceutical Co., Ltd. | Imidazopyridine compound |
WO2011009883A1 (fr) | 2009-07-23 | 2011-01-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Agonistes sélectifs du récepteur cb2 destinés à être utilisés dans la prévention ou le traitement d'une maladie hépatique alcoolique |
DK2464645T3 (en) | 2009-07-27 | 2017-10-23 | Gilead Sciences Inc | CONDENSED, HETEROCYCLIC COMPOUNDS AS IRON CHANNEL MODULATORS |
MX2012015096A (es) | 2010-07-02 | 2013-05-28 | Gilead Sciences Inc | Compuestos heterociclicos fusionados como moduladores del canal ion. |
WO2012037349A2 (fr) * | 2010-09-17 | 2012-03-22 | Glaxosmithkline Llc | Composés |
WO2012037351A1 (fr) * | 2010-09-17 | 2012-03-22 | Glaxosmithkline Llc | Composés |
AU2012253653A1 (en) | 2011-05-10 | 2013-05-02 | Gilead Sciences, Inc. | Fused heterocyclic compounds as sodium channel modulators |
UY34171A (es) | 2011-07-01 | 2013-01-31 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal iónico |
NO3175985T3 (fr) | 2011-07-01 | 2018-04-28 | ||
US8940737B2 (en) | 2011-10-14 | 2015-01-27 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
CN103987711B (zh) | 2011-10-14 | 2016-08-24 | 艾伯维公司 | 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物 |
TN2017000407A1 (en) * | 2015-03-27 | 2019-01-16 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives. |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1470084A1 (de) | 1964-08-19 | 1969-05-29 | Merck Ag E | Verfahren zur Herstellung von substituierten Piperidin-derivaten |
US5532237A (en) | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
EP0887340A4 (fr) * | 1996-02-06 | 2000-03-29 | Japan Tobacco Inc | Composes chimiques et utilisation pharmaceutique |
JP2001516361A (ja) * | 1997-03-18 | 2001-09-25 | スミスクライン・ビーチャム・コーポレイション | 新規カンナビノイド受容体作動薬 |
FR2783246B1 (fr) | 1998-09-11 | 2000-11-17 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les medicaments les contenant |
-
2001
- 2001-07-30 RU RU2003102888/04A patent/RU2272030C2/ru not_active IP Right Cessation
- 2001-07-30 MX MXPA03000952A patent/MXPA03000952A/es unknown
- 2001-07-30 BR BR0112883-3A patent/BR0112883A/pt not_active IP Right Cessation
- 2001-07-30 EP EP01953336A patent/EP1306373B1/fr not_active Expired - Lifetime
- 2001-07-30 AU AU2001275798A patent/AU2001275798A1/en not_active Abandoned
- 2001-07-30 JP JP2002516267A patent/JP4982937B2/ja not_active Expired - Fee Related
- 2001-07-30 PL PL01362916A patent/PL362916A1/xx unknown
- 2001-07-30 AT AT01953336T patent/ATE362470T1/de not_active IP Right Cessation
- 2001-07-30 US US10/333,591 patent/US6956033B2/en not_active Expired - Fee Related
- 2001-07-30 HU HU0303070A patent/HUP0303070A2/hu unknown
- 2001-07-30 IL IL15408201A patent/IL154082A0/xx unknown
- 2001-07-30 CN CNA01816496XA patent/CN1466577A/zh active Pending
- 2001-07-30 WO PCT/JP2001/006541 patent/WO2002010135A1/fr active IP Right Grant
- 2001-07-30 DE DE60128476T patent/DE60128476D1/de not_active Expired - Lifetime
- 2001-07-30 NZ NZ523839A patent/NZ523839A/en unknown
- 2001-07-30 CA CA002417156A patent/CA2417156A1/fr not_active Abandoned
- 2001-07-30 KR KR10-2003-7001424A patent/KR20030017660A/ko not_active Application Discontinuation
- 2001-07-30 CZ CZ2003284A patent/CZ2003284A3/cs unknown
-
2003
- 2003-01-22 ZA ZA200300619A patent/ZA200300619B/xx unknown
- 2003-01-30 NO NO20030490A patent/NO20030490L/no unknown
Also Published As
Publication number | Publication date |
---|---|
MXPA03000952A (es) | 2003-09-05 |
US6956033B2 (en) | 2005-10-18 |
BR0112883A (pt) | 2003-06-24 |
CZ2003284A3 (cs) | 2003-09-17 |
NO20030490D0 (no) | 2003-01-30 |
US20040077643A1 (en) | 2004-04-22 |
IL154082A0 (en) | 2003-07-31 |
ZA200300619B (en) | 2004-05-20 |
JP4982937B2 (ja) | 2012-07-25 |
HUP0303070A2 (hu) | 2003-12-29 |
CA2417156A1 (fr) | 2003-01-23 |
NZ523839A (en) | 2005-07-29 |
KR20030017660A (ko) | 2003-03-03 |
RU2272030C2 (ru) | 2006-03-20 |
WO2002010135A1 (fr) | 2002-02-07 |
EP1306373A4 (fr) | 2004-09-01 |
ATE362470T1 (de) | 2007-06-15 |
EP1306373A1 (fr) | 2003-05-02 |
DE60128476D1 (de) | 2007-06-28 |
PL362916A1 (en) | 2004-11-02 |
EP1306373B1 (fr) | 2007-05-16 |
CN1466577A (zh) | 2004-01-07 |
NO20030490L (no) | 2003-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001275798A1 (en) | 3,4-dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient | |
HU9500240D0 (en) | New prolin-amide derivatives and pharmaceutical compositions containing them as active component | |
JO2311B1 (en) | Alkyl inhibitors Ariel phosphodiesterase-4 | |
IL162214A (en) | Pyridine derivatives and pharmaceutical compositions containing the same | |
WO2002060859A3 (fr) | Derives cycliques utilises comme modulateurs de l'activite des recepteurs de chimiokines | |
WO2003000699A8 (fr) | Derives de 1-oxa-2,8-diazaspiro[4,5]dec-2-ene servant d'antalgiques | |
PL374325A1 (en) | Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof | |
GB9927844D0 (en) | Chemical compounds | |
WO2002024697A1 (fr) | Composes spiro et inhibiteurs de molecules d'adhesion contenant ces composes comme ingredient actif | |
AU3955199A (en) | Remedies for itching containing PGD2 antagonists | |
WO2003015780A3 (fr) | Isoxazolopyridinones | |
EP1254898A4 (fr) | Derives heterocycliques condenses au benzene et medicaments contenant ceux-ci comme ingredients actifs | |
WO2003024941A1 (fr) | Composes de naphtalene et leur utilisation comme medicament | |
WO2004048381A3 (fr) | Nouveaux composes de pyrazoloazepine utilises en tant qu'agents pharmaceutiques | |
HK1083839A1 (en) | Indoline compound and medicinal use thereof | |
AU2001284476A1 (en) | Novel crystals of 1,3,4-oxadiazole derivative, process for producing the crystals and medicines containing the same as the active ingredient | |
WO2004089352A3 (fr) | Combinaison pharmaceutique pour le traitement de l'hypertonie spastique et/ou la douleur | |
IL154625A0 (en) | Novel crystals of n-hydroxy-2 (s)-methyl-5-ethoxymethoxy-4-(s)-[n-(4-phenoxyphenylcarbonyl) amino] pentanamide, process for their production and medicines containing the crystals as the active ingredient | |
CA2239053A1 (fr) | Derives d'ethane diphenyle pyridyle utilises comme inhibiteurs de pde iv | |
EP1466909A4 (fr) | Derives d'acide halogenobenzylaminopropionique | |
WO2000078751A3 (fr) | Composes chimiques | |
TH39271A (th) | อนุพันธ์สไปโร-ไพเพอริดีน และการใช้งานของสิ่งเหล่านั้นเป็นสารอายุรเวช |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |